Drugs / Pembrolizumab (+) Berahyaluronidase Alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06099782 | Dec 2023 → Apr 2025 overdue | melanoma, non-small cell lung carcinoma, renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab (+) Berahyaluronidase Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099782 ↗ |
| Route | Subcutaneous | “Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.” NCT06099782 ↗ |